Skip to content

Author

A. Kalyan

We have 3 of 112 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Interventional Radiology as the Most Utilized Treatment Specialty for Hepatocellular Carcinoma: A 25-Year Multidisciplinary Analysis at a High-Volume Academic Transplant Center.

PURPOSE To characterize the longitudinal role of interventional radiology (IR) in multidisciplinary hepatocellular carcinoma (HCC) care over 25 years at a high-volume liver transplant center, and to evaluate changes in IR utilization and procedural composition following FDA approval of atezolizumab plus bevacizumab (At...

Arsalan Nadeem, L. Kulik, A. Kalyan et al. · 0 citations
Open access Oct 2026

Multimodal Immune Profile Score (IPS) as a Pan-Cancer Biomarker for Stratifying Outcomes of Immune Checkpoint Inhibitor Benefit in Microsatellite Stable Colorectal Cancer and Rare Solid Tumors

Background Immune checkpoint inhibitor (ICI) therapies have revolutionized oncology, but identifying patients who benefit remains a challenge, particularly in populations where ICIs are not the standard of care, including microsatellite stable colorectal cancer (MSS CRC) and rare solid cancers. We evaluated real-world...

M. Ting-Lin, E. Antonarakis, X. Wang et al. · 0 citations
Open access Aug 2026

Addition of High-Dose Vitamin D3 to Standard Treatment in Patients with Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703)

High-dose vitamin D3 added to standard treatment improved progression-free survival (PFS) compared to standard-dose vitamin D3 in patients with metastatic colorectal cancer (mCRC) in a phase 2 randomized clinical trial.

K. Ng, F. Ou, T. Zemla et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.